β-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts

Circulation

Volumn 109, Issue 22, 2004, Pages 2773-2779

  Asanuma, Hiroshi ^a   Minamino, Tetsuo ^a   Sanada, Shoji ^a   Takashima, Seiji ^a   Ogita, Hisakazu ^a   Ogai, Akiko ^b   Asakura, Masanori ^a   Liao, Yulin ^a   Asano, Yoshihiro ^a   Shintani, Yasunori ^a   Kim, Jiyoong ^b   Shinozaki, Yoshiro ^c   Mori, Hidezo ^b   Node, Koichi ^a   Kitamura, Soichiro ^b   Tomoike, Hitonobu ^b   Hori, Masatsugu ^a   Kitakaze, Masafumi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenosine; Infarction; Ischemia; Reperfusion; Stress

Indexed keywords

8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ECTO 5' NUCLEOTIDASE; SUPEROXIDE DISMUTASE; XANTHINE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLATERAL CIRCULATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; UMBILICAL VEIN; VASODILATATION;

5'-NUCLEOTIDASE; ADENOSINE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; CELLS, CULTURED; CORONARY CIRCULATION; DOGS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATIVE STRESS; PROPANOLAMINES; PROPRANOLOL;

EID: 2942602676     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000130917.12959.04     Document Type: Article

References (25)

1. Saxenhofer H, Morger D, Weidmann P, et al. Modulation of noradrenergic but not angiotensinergic blood pressure control by beta-blockade with carteolol. J Hypertens. 1991;9:1049-1056.
2. Silke B, Verma SP, Hussain M, et al. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris. Br J Clin Pharmacol. 1983;16:529-535.
3. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
4. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
5. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
6. Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(suppl 2):S82-S88.
7. Gretzer I, Hjemdahl P. Differences between the effects of metoprolol and prazosin on the forearm vasculature in primary hypertension. J Hypertens. 1997;15:1317-1326.
8. Oettl K, Greilberger J, Zangger K, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol. 2001;62:241-248.
9. Huang WH, Wang Y, Askari A. (Na+/K+)-ATPase: inactivation and degradation induced by oxygen radicals. Int J Biochem. 1992;24:621-626.
10. Guerra L, Cerbai E, Gessi S, et al. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea pig ventricular myocytes. Br J Pharmacol. 1996;118:1278-1284.
11. Kitakaze M, Hori M, Takashima S, et al. Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs: a role of 5′-nucleotidase activity. Circ Res. 1992;71:558-566.
12. Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999;63:231-243.
13. Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation. 1995;92:950-961.
14. Bergmeyer HU. Methods of Enzymatic Analysis. 1st ed. New York, NY: Academic Press Inc; 1963:266-270.
15. Smith K, Varon HH, Race GJ, et al. Serum 5′-nucleotidase in patients with tumor in the liver. Cancer. 1965;19:1281-1285.
16. Kitakaze M, Hori M, Morioka T, et al. Alpha1-adrenoceptor activation mediates the infarct size limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity and adenosine release. J Clin Invest. 1994;93:2197-2205.
17. Mori H, Haruyama S, Shinozaki Y, et al. New nonradioactive microspheres and more sensitive X-ray fluorescence to measure regional blood flow. Am J Physiol. 1992;263:HI946-HI957.
18. Snedecor GW, Cochran WG. Statistical Methods. Ames, Iowa: Iowa State University Press; 1972:258-298.
19. Steel RGD, Torrie JH. Principles and Procedures of Statistics: A Biomedical Approach. 2nd ed. New York, NY: McGraw-Hill Publishing Co; 1980:137-238.
20. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action anti-hypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1995;16(suppl F):38-42.
21. 1-Adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res. 1987;60:631-639.
22. Brodde OE, Zerkowski HR, Borst HG, et al. Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. Eur Heart J. 1989;10(suppl B):38-44.
23. Babbitt TG, Virmani R, Norton R Jr, et al. Adenosine administration during reperfusion after 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J. 1990;120:808-818.
24. Parmely MJ, Zhou WW, Edwards CK, et al. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol. 1993;151:389-396.
25. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-2089.